Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

Pathogen (Target Population)

Vaccine Envisaged

Annualized Present Value of Potential Health Benefits (IME Units)

Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits (dollars)

Rabies virus

(Individuals at high risk, plus post-exposure prophylaxis) (As above)

Vero cell

41,910

146,811,503

Glycoprotein produced by rDNA technology in mammalian cells

37,983

138,655,304

(Birth cohort in areas of high risk)

Attenuated live vector virus containing gene for protective glycoprotein antigen

8,260

15,506,192

Respiratory syncytial virus

(Infants)

Polypeptides produced by recombinant DNA technology

52,412

1,964,436,106

Attenuated live virus

59,559

982,843,053

Rotavirus

(Infants, 0–6 months)

Attenuated high passage bovine rotavirus

521,852

852,737,494

Attenuated low passage bovine rotavirus

450,795

655,395,369

Rhesus monkey rotavirus

450,795

655,895,369

Salmonella typhi

(Children; young adults at risk; travelers from developed countries to endemic areas)

Attenuated ga1E mutant S. typhi strain TY21a

431,471

358,039,747

Aromatic amino acid dependent strains of S. typbi

194,745

152,153,450

Shigella spp.

(Infants at birth; elderly for epidemic strains)

Probably plasmid mediated outer membrane protein invasion determinant (a small number of promising options need to be investigated to determine best approach)

222,096

91,603,782

Streptococcus A

(Children, < 3–4 years)

Synthetic M protein segment (excluding portions cross-reacting with human tissue)

180,513

554,167,844

Streptococcus pneumoniae

(Infants)

Conjugated polysaccharides, polyvalent

1,363,943

1,310,290,738

Vibrio cholera

(Children, especially <2 years)

Genetically defined live mutant V. cholerae (A−B+ or A−B−) with respect to toxin subunit synthesis

94,986

23,788,751

Inactivated antigens

65,548

43,571,553

Yellow fever virus

(Young children)

Attenuated live virus produced in cell culture

11,127

93,049,382

aUnadjusted annualized present values of potential health benefits represent a situation where resource constraints are not a concern: no vaccine candidate is affordable if the willingness to pay per IME averted is $100 or less.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement